Japan pet cancer therapeutics market revenue was US$ 14.4 Million in 2022 and is forecast to reach a valuation of US$ 26.1 Million by 203, growing at a CAGR of 7.3% during the forecast period 2023-2031.
Request Sample Copy of Research Report @ https://www.astuteanalytica.com/request-sample/japan-pet-cancer-therapeutics-market
In Japan, there is a rising trend in the need for pet cancer treatment. In Japan, the number of pets treated for cancer has climbed by 20% over the previous five years, according to research by the Japanese Animal Hospital Association.
Innovative anti-cancer drugs called pet cancer therapies may be able to lessen the effects of cancerous cells. On the basis of the type of tumor and its stage, pet cancer treatments are often either monotherapy or combination therapy. It addresses mammary, canine, and feline lymphoma, mast cell cancer, melanoma, and squamous cell cancer. Immunotherapy, radiation therapy, chemotherapy, and biopsy are a few of the common targeted therapies.
Factors Pushing the Growth of the Market
This rise in demand is due to a number of factors. First, more Japanese people are getting pets. Japan had an estimated 7.1 million pet-owning households in 2019, an increase of 1.5 million from 2010. Cancer risk increases as the number of pets increases. Second, thanks to improvements in veterinary medicine, pets are living longer. As a result, as individuals get older, they have a high chance of getting cancer.
The Japan pet cancer therapeutics industry is seeing an increase in Japanese pet owners’ awareness of the value of treatment of cancer and early detection. Pet owners can learn about the most recent developments in cancer therapy and make knowledgeable decisions regarding their pet’s care thanks to social media and the internet.
Many veterinarians are increasingly providing specialized services and treatments in response to the rising demand for pet cancer therapy. Even dedicated pet cancer clinics have been developed by some veterinarians. Many pet owners are eager to spend whatever it takes to give their beloved furry buddy a fighting chance, despite the fact that therapy might be expensive.
In Japan, cancer is the most common cause of death for dogs and cats, and by 2031, the market for cancer therapies for pets is estimated to reach 26.1 million. Analysis reveals that a variety of variables, such as an aging pet population, a greater awareness of pet health issues, and a desire for natural and holistic therapies drive the market. In Japan, surgery is the most widely used kind of cancer treatment for pets, followed by radiation and chemotherapy. Acupuncture, herbal therapy, and homeopathy are examples of less invasive, more natural treatments that are becoming more popular. For instance, according to our research, 34% of cat owners and 47% of dog owners, respectively, would be open to buying pet cancer medicines online.
The leading businesses in this sector are well-known internationally and hold sizable market shares. Given that they have chosen a variety of products to target various pet cancers, the players are extremely competitive. Key firms have put strategies, including ongoing product releases, strategic alliances, and worldwide coverage into place to acquire an advantage in the global market.
Companies must stay current with emerging ideas and technologies as the Japanese market for treating pet cancer expands. Businesses can use this study to assist them to decide where to concentrate their resources in order to stay competitive.
The chemotherapy segment is leading the Japan pet cancer therapeutics industry and is likely to remain dominant over the analysis years due to the rapid reactions of the pets to the treatment.
Chemotherapy is so well-liked among pet owners in Japan for a variety of reasons.
First, compared to other cancer therapies, chemotherapy is comparatively inexpensive.
Second, it is typically regarded as being less invasive than alternatives like surgery or radiation treatment.
Lastly, busy pet owners can receive chemotherapy on an outpatient basis, which is convenient. Chemotherapy does, of course, have certain negative effects. In the market, nausea, lethargy, and vomiting are the most frequent adverse effects. However, these adverse effects may manage with the right supportive care from a veterinarian.
Route of Administration
The oral segment dominated the Japan industry and will have the highest share in the upcoming years. Compared to other administration methods like intramuscular or intravenous injection, the oral route is more practical and less invasive. Since pets commonly take drugs by mouth, oral drug administration allows for a more natural treatment option for them. The potential negative effects of other delivery methods, such as injection site pain, are also avoided by using this method. Oral medicine delivery also makes it simpler for pet owners to keep an eye on their animals because they can easily see if they are taking the prescription or not. This is crucial since some pets could object to receiving their medication orally or through an injection. Due to its ease, safety, and effectiveness, the oral route of drug delivery is generally the one most frequently used in Japan to treat pet cancer.
Compared to cats, dogs have a substantially greater incidence of cancer. The Flint Animal Cancer Center estimates that one in every four dogs may develop cancer. As a result, the increased incidence of cancer in dogs is driving market expansion.
The high rate of canine cancer in Japan is caused by a variety of reasons as there are more dogs living near one another in the country because of the high population density. This raises the likelihood of the disease spreading. Furthermore, Japanese cuisine is rich in processed fish and meats, which have carcinogens that can raise the chance of developing cancer.
The market includes numerous cancer forms that are particularly common in dogs. One is a malignancy of the lymphatic system called lymphoma. All dogs are susceptible to lymphoma, although the prevalence is significantly higher in Japan. Gastrointestinal cancer, which can affect the intestines, stomach, and rectum, is another common form of cancer in Japanese dogs. All dogs can develop gastrointestinal cancer, which is also rather frequent, but the incidence is again significantly greater in Japan.
Directly Purchase a copy of report with TOC @ https://www.astuteanalytica.com/inquire-before-purchase/japan-pet-cancer-therapeutics-market
List of Leading Companies
- Nippon Zenyaku Kogyo
- Sumitomo Pharma Animal Health Co.
- Zoetis Inc.
- AB Science
- Pfizer Inc.
- Elanco Animal Health Incorporated
- Torigen Pharmaceuticals Inc
- Rhizen Pharmaceuticals AG
- ELIAS Animal Health LLC
- Regeneus Ltd.
- Karyopharm Therapeutics
- Boehringer Ingelheim International GmbH
- Other Prominent Players
- Targeted Therapy
- Combination Therapy
By Route Of Administration
- Mast Cell Cancer
- Mammary and Squamous Cell Cancer
By Distribution Channel
- Veterinary Hospitals & Clinical Pharmacies
- Online Pharmacies
- Retail Pharmacies
To gain more insights into the market with a detailed table of content and figures, click here: https://www.astuteanalytica.com/industry-report/japan-pet-cancer-therapeutics-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Follow US: LinkedIn | Twitter